The global Microscopic Polyangiitis (MPA) Treatment market size is projected to reach, at a CAGR of 7.5% during 2019-2028.

With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Microscopic Polyangiitis (MPA) Treatment market to help players in achieving a strong market position.

Top Driver: rising development of new treatments for MPA and robust pipeline drug

The global microscopic polyangiitis (MPA) treatment market growth is majorly driven by the rising development of new treatments for MPA and robust pipeline drugs. Some of the pipeline drugs for the treatment of microscopic polyangiitis are Abatacept, IFX 1, among othersFood and Drug Administration (FDA) approval for conducting phase II clinical trials of IFX-1 for treatment of anti-neutrophil cytoplasmic autoantibody (ANCA) vasculitis, presence of ANCA indicates that patient is suffering from microscopic polyangiitis (MPA). IFX-1, an inhibitor of the complement system, neutralizes C5a component without affecting the normal immune functions. Hence, increasing clinical trials for the development of new treatment for MPA is expected to boost the growth of microscopic polyangiitis market over the forecast period.

The increasing approvals by regulatory bodies such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), Medicines and Healthcare products Regulatory Agency (MHRA), among others for several drugs for the treatment of MPA is further driving the growth of the market.

Rituximab to Make Crucial Contribution for Growth of Global Microscopic Polyangiitis Treatment Market

The treatment of microscopic polyangiitis is predicated on several factors, including disease severity and organ involvement. Commonly, MPA is treated with corticosteroids like prednisone utilized in combination with other medications that suppress the system and reduce inflammation. However, even with treatment, MPA may be a chronic condition with periods of relapse and remission, so ongoing medical aid and monitoring is necessary. A number of the drug available for the treatment of MPA is Rituximab (Rituxan), Cyclophosphamide (Cytoxan), Azathioprine, Prednisone, Avacopan, et al. In 2011, the U.S. Food and Drug Administration (FDA) approved rituximab for the treatment of MPA and GPA. (Biologic medications are complex proteins derived from living organisms. they aim certain parts of the system to regulate inflammation.). Rituximab is predicted to realize maximum share over the forecast period 2019-2028.

 On the opposite hand, cyclophosphamide is growing at a big rate of growth over the forecast period. It’s a chemotherapy-type drug which blocks the abnormal growth of certain cells within the body, together with prednisone. Prednisone is usually started at a high dose then tapered off slowly. Cyclophosphamide lowers the body’s ability to fight infection, hence usually limited to a three- to six-month period and replaced by less toxic medications like mycophenolate mofetil and azathioprine, or methotrexate, a drug commonly won’t to treat atrophic arthritis. Some milder sorts of MPA are typically treated with a mixture of prednisone and methotrexate.

North America dominated to witness fastest growth in Global Microscopic Polyangiitis Treatment Market

North America region is dominating the worldwide microscopic polyangiitis (MPA) treatment market accounting for the utmost market share in 2019, thanks to the increasing development of medicine for the treatment of MPA. Within the us, the annual incidence of microscopic polyangiitis is 3.6 cases per million persons, and therefore the prevalence is one to 3 cases per 100,000 populations. In September 2019, Roche received the U.S. Food and Drug Administration (FDA) approval for Rituxan® (rituximab), together with glucocorticoids, for the treatment of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) in paediatric patients two years aged and older.

On the opposite hand, Europe microscopic polyangiitis market is projected to grow at a big CAGR over the forecast period, thanks to increasing clinical trials and approval of medicine. As an example Bristol-Myers Squibb Company is conducting phase III clinical trial clinical trials for Abatacept (Orencia), which is predicted to be completed by September 2022. Orencia may be a recombinant protein that inhibits the T cell activation pathway thereby suppressing the system.

Players to Focus on Microscopic Polyangiitis Treatment Market

The microscopic polyangiitis (MPA) treatment market is very competitive and consists of several major players and emergence of latest players within the market. A number of the key players which are contributing to the expansion of the market are

• ChemoCentryx Inc.,
• Celltrion, Inc.,
• Teijin Pharma Ltd,
• Sandoz International GmbH (Novartis Division),
• TTY Biopharm Company Ltd,
• Genentech, Inc.,
• InflaRx N.V.,
• Bristol-Myers Squibb Company,
• Amerigen Pharmaceuticals Limited,

The main players are adopting several growth strategies like product launches, clinical trials, acquisitions, and collaborations, which are contributing to the expansion of the microscopic polyangiitis (MPA) treatment market globally.

Israeli generics giant Teva Pharmaceutical Industries; on 4th May 2020, Israeli generics giant Teva Pharmaceutical Industries and partner, South Korean biotechnology company Celltrion, launched their rituximab biosimilar Truxima (TL011) within the US. Truxima (rituximab-abbs) is now available within the US for treatment of patients with non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukaemia (CLL), atrophic arthritis , granulomatosis with polyangiitis (Wegener’s granulomatosis) and microscopic polyangiitis.

Pfizer In January 2020, Pfizer announced to introduce three new biosimilars this year. the corporate plans to launch Avastin biosimilar Zirabev (bevacizumab-bvzr); Rituxan biosimilar Ruxience (rituximab-pvvr); and Herceptin biosimilar Trazimera (trastuzumab-qyyp). Ruxience is out there for the treatment of adult patients with non-Hodgkin’s lymphoma, chronic leukemia , and granulomatosis with polyangiitis and microscopic polyangiitis.

Scope of the Report

By Type

• Avacopan
• Immune Globulin
• Rituximab Biosimila

By Application

• Hospital
• Clinic

By Region

• North America
• Europe
• Asia Pacific
• SAMEA

Key Reasons to Purchase this Report 

1. It provides a technological development map over time to understand the growth rate of the industry.

2. The report offers a dynamic method to various factors that drive or restrain the growth of the market.

3. It renders definite analysis for changing competitive dynamics.

4. It builds a seven-year estimate based on how the market is predicted to grow.